Anterogencoltd Stock Total Debt
| 065660 Stock | KRW 19,880 520.00 2.69% |
AnterogenCoLtd fundamentals help investors to digest information that contributes to AnterogenCoLtd's financial success or failures. It also enables traders to predict the movement of AnterogenCoLtd Stock. The fundamental analysis module provides a way to measure AnterogenCoLtd's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to AnterogenCoLtd stock.
AnterogenCoLtd |
AnterogenCoLtd Company Total Debt Analysis
AnterogenCoLtd's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Based on the latest financial disclosure, AnterogenCoLtd has a Total Debt of 0.0. This is 100.0% lower than that of the Healthcare sector and about the same as Pharmaceuticals (which currently averages 0.0) industry. The total debt for all Republic of Korea stocks is 100.0% higher than that of the company.
AnterogenCoLtd is currently under evaluation in total debt category among its peers. Total debt of Pharmaceuticals industry is presently estimated at about 6.83 Billion. AnterogenCoLtd adds roughly 0.0 in total debt claiming only tiny portion of equities listed under Pharmaceuticals industry.AnterogenCoLtd Fundamentals
| Return On Equity | -5.92 | |||
| Return On Asset | -0.0231 | |||
| Profit Margin | (1.32) % | |||
| Operating Margin | (0.77) % | |||
| Current Valuation | 836.51 B | |||
| Shares Outstanding | 7.95 M | |||
| Shares Owned By Insiders | 21.02 % | |||
| Shares Owned By Institutions | 5.63 % | |||
| Price To Sales | 103.53 X | |||
| Revenue | 8.12 B | |||
| Gross Profit | 1.72 B | |||
| EBITDA | (2.96 B) | |||
| Net Income | (553.98 M) | |||
| Cash And Equivalents | 6.97 B | |||
| Debt To Equity | 43.70 % | |||
| Current Ratio | 3.83 X | |||
| Cash Flow From Operations | (3.05 B) | |||
| Beta | 0.37 | |||
| Market Capitalization | 108.41 B | |||
| Total Asset | 136.7 B | |||
| Net Asset | 136.7 B |
About AnterogenCoLtd Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze AnterogenCoLtd's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AnterogenCoLtd using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AnterogenCoLtd based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Other Information on Investing in AnterogenCoLtd Stock
AnterogenCoLtd financial ratios help investors to determine whether AnterogenCoLtd Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AnterogenCoLtd with respect to the benefits of owning AnterogenCoLtd security.